ARTICLE | Emerging Company Profile

Kelonia: redirecting in vivo gene therapy

Kelonia has a team of bluebird veterans and a $50 million series A round to tackle gene therapy’s delivery problem

April 28, 2022 10:37 PM UTC

Kelonia is taking on one of the biggest challenges in gene therapy development with a new in vivo lentivirus-based platform designed to move the modality outside the liver. 

For its first program, the company is using its gene therapy delivery platform to add CARs to T cells inside the body, making it the latest company to join the small but growing in vivo CAR T cell field...